InflaRx (IFRX) Share-based Compensation (2019 - 2026)
InflaRx's (IFRX) quarterly Share-based Compensation came in at $1.1 million in Q1 2026, down 57.76% year-on-year from $2.6 million in Q1 2025, and up 263.7% quarter-over-quarter from $302937.7 in Q4 2025.
InflaRx (IFRX) Share-based Compensation (2019 - 2026) Analysis & Trends
InflaRx has disclosed Share-based Compensation across 8 years of filings, most recently posting $1.1 million for Q1 2026.
- Share-based Compensation for Q1 2026 came in at $1.1 million, down 57.76% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.4 million (down 32.8% YoY), and the FY2025 annual result was $5.2 million, up 19.08% from the prior year.
- Share-based Compensation came in at $1.1 million for Q1 2026 at InflaRx, up from $302937.7 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $2.8 million in Q1 2022 to a low of $302937.7 in Q4 2025.
- The 5-year median for Share-based Compensation is $1.1 million (2026), against an average of $1.2 million.
- Across the five-year window, Share-based Compensation jumped 95.98% in 2022 and plunged 57.76% in 2026, its largest moves.
- InflaRx's Share-based Compensation stood at $472716.3 in 2022, then climbed by 3.11% to $487398.6 in 2023, then retreated by 25.48% to $363215.6 in 2024, then retreated by 16.6% to $302937.7 in 2025, then jumped by 263.7% to $1.1 million in 2026.
- The last three Share-based Compensation figures came in at $1.1 million (Q1 2026), $302937.7 (Q4 2025), and $696615.4 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | 305,000.00 |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 166.40 Mn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | 26.47 Mn |
| 10 | InflaRx | 764.68 Mn | 764.68 Mn | 10,877.40 | 1.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.10 Mn |
| Mar 31, 2026 | 1.10 Mn |
| Dec 31, 2025 | 302,937.67 |
| Dec 31, 2025 | 302,937.67 |
| Sep 30, 2025 | 696,615.38 |
| Sep 30, 2025 | 696,615.38 |
| Jun 30, 2025 | 1.25 Mn |
| Jun 30, 2025 | 1.25 Mn |
| Mar 31, 2025 | 2.61 Mn |
| Mar 31, 2025 | 2.61 Mn |
| Dec 31, 2024 | 363,215.58 |
| Dec 31, 2024 | 363,215.58 |
| Sep 30, 2024 | 716,142.35 |
| Sep 30, 2024 | 716,142.35 |
| Jun 30, 2024 | 1.31 Mn |
| Jun 30, 2024 | 1.31 Mn |
| Mar 31, 2024 | 2.02 Mn |
| Mar 31, 2024 | 2.02 Mn |
| Dec 31, 2023 | 487,398.63 |
| Dec 31, 2023 | 487,398.63 |